
Get exclusive money-saving offers and guides
Straight to your inbox
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
VBI Vaccines Inc is a biotechnology business with stocks listed in the US. VBI Vaccines shares (VBIV) are listed on the NASDAQ and all prices are listed in US Dollars. Here's how to invest if you're based in Australia.
Our top pick for
US stocks
Our top pick for
Cheap broker fees
Our top pick for
Long-term investing
52-week range | US$0.69 - US$6.93 |
---|---|
50-day moving average | US$3.4715 |
200-day moving average | US$3.1909 |
Target price | US$6.5 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | US$-0.758 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Revenue TTM | US$1.5 million |
---|---|
Gross profit TTM | US$-5,683,000 |
Return on assets TTM | -14.92% |
Return on equity TTM | -31.74% |
Profit margin | 0% |
Book value | 0.685 |
Market capitalisation | US$815.7 million |
TTM: trailing 12 months
There are currently 42.1 million VBI Vaccines shares held short by investors – that's known as VBI Vaccines's "short interest". This figure is 5.8% down from 44.7 million last month.
There are a few different ways that this level of interest in shorting VBI Vaccines shares can be evaluated.
VBI Vaccines's "short interest ratio" (SIR) is the quantity of VBI Vaccines shares currently shorted divided by the average quantity of VBI Vaccines shares traded daily (recently around 7.3 million). VBI Vaccines's SIR currently stands at 5.8. In other words for every 100,000 VBI Vaccines shares traded daily on the market, roughly 5800 shares are currently held short.
However VBI Vaccines's short interest can also be evaluated against the total number of VBI Vaccines shares, or, against the total number of tradable VBI Vaccines shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case VBI Vaccines's short interest could be expressed as 0.17% of the outstanding shares (for every 100,000 VBI Vaccines shares in existence, roughly 170 shares are currently held short) or 0.2321% of the tradable shares (for every 100,000 tradable VBI Vaccines shares, roughly 232 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against VBI Vaccines.
Find out more about how you can short VBI Vaccines stock.
We're not expecting VBI Vaccines to pay a dividend over the next 12 months.
VBI Vaccines's shares were split on a 1:40 basis on 2 May 2016. So if you had owned 40 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your VBI Vaccines shares – just the quantity. However, indirectly, the new 3900% higher share price could have impacted the market appetite for VBI Vaccines shares which in turn could have impacted VBI Vaccines's share price.
Over the last 12 months, VBI Vaccines's shares have ranged in value from as little as US$0.69 up to US$6.93. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while VBI Vaccines's is 1.992. This would suggest that VBI Vaccines's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology in Israel, the United States, and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for a functional cure of chronic hepatitis B. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the target virus to elicit a potent immune response. Its lead eVLP program candidates include VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study; and VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial. In addition, the company engages in the development of vaccine platforms and products for licensing to pharmaceutical companies and biotechnology companies. It primarily serves physicians and pharmacists through direct sales. VBI Vaccines Inc. has collaboration and license agreements with Brii Biosciences Limited; and GlaxoSmithKline Biologicals S.A. It also has a collaboration with the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome; and a partnership with Syneos Health, Inc. for the commercialization of VBI's 3-antigen prophylactic hepatitis B vaccine in the United States, Europe, and Canada, which is in pending regulatory approvals. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts.
From Membership Rewards Points to savings on first and business class flights, this charge card is packed with features to help you manage business spending.
From the best sheets for summer to the most luxurious threads, these are the seven best bed sheets you can get in Australia right now.
Everything we know about the Bumble IPO, plus information on how to buy in.
Steps to owning and managing MicroStrategy shares.
Everything we know about the Superhero IPO, plus information on how to buy in.
Everything we know about the Kuaishou IPO, plus information on how to buy in.
Everything we know about the Coinbase IPO, plus information on how to buy in.
Everything we know about the Databricks IPO, plus information on how to buy in.
Steps to owning and managing Ligand Pharmaceuticals shares.
You can't access Robinhood in Australia, so here are five low-cost alternatives to trade US stocks.